Allogeneic hematopoietic cell transplantation has an established role in treating adult acute lymphoblastic leukemia with survival using adult unrelated donors approaching those of sibling donors. Our aim was to determine the role of mismatched unrelated cord blood grafts in transplantation for 802 adults with acute lymphoblastic leukemia in first or second complete remission. Using Cox regression we compared outcomes after 116 mismatched single or double cord blood, 546 peripheral blood progenitor-cells and 140, bone marrow.
Patient and disease characteristics of recipients were similar except cord blood recipients were younger, more likely to be non-Caucasians and to have low white blood cell count at diagnosis. There were differences in donor-recipient human leukocyte antigen-match between the donor sources. Most adult donor transplants were matched at the allele-level considering human leukocyte antigen-A, -B, -C and -DRB1. In contrast, most cord blood transplants were mismatched and considered antigen-level match; 57% were mismatched at 2-and 29% at 1-loci whereas only 29% of adult donor transplants were mismatched at 1 locus and none at 2-loci. There were no differences in the 3-year probabilities of survival between cord blood (44%), matched (44%) and mismatched (43%) adult donor transplants.
Cord blood transplants had slower engraftment, less grade 2-4 acute but similar chronic graftversus-host disease, relapse, and transplant-related mortality. Cord blood grafts achieved similar survival to matched or mismatched unrelated donor grafts and should be considered a valid alternative stem-cell source for adults with acute lymphoblastic leukemia in the absence of a matched unrelated adult donor.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) is the most effective antileukemic therapy for adults with high-risk acute lymphoblastic leukemia (ALL) in first complete remission (CR1) but results are compromised by high transplant related mortality especially in patients over the age of 35 years. 1, 2 Allogeneic HCT is also offered to adults with ALL in CR2. Recent large prospective donor-versus-no donor analyses show that matched sibling allografting produces superior outcomes to chemotherapy and such transplants remains the standard of care in the highest risk, Philadelphia-positive cohort. Philadelphia-negative ALL in CR1 at high risk of relapse. 2 This study of 169 patients demonstrated 40% 5-year survival in a high risk cohort but also a high transplant related mortality of 42%.
For adults with ALL in CR2 allogeneic transplantation is the treatment of choice with sibling allografts achieving disease-free survival rates of 25-40%. The outcome of URD transplantation for ALL in CR2 is less successful with the UKALLXII study reporting 16% survival 3 although some recent German data are more encouraging. 4 Most conditioning regimens have involved the use of total body irradiation (TBI). In younger sibling donor transplants (median age 18 years) for ALL, doses of TBI exceeding 13 Gy resulted in superior survival. 5 More recently there have been two small registry based reports of the results of reduced intensity conditioning regimens; these studies involved small numbers of patients and did not include recipients of cord blood. 6, 7 The role of URD transplantation in adults with ALL in CR1 is being further evaluated in current prospective trials such as the current United Kingdom ALL XIV trial but about 15-30% of eligible patients do not have a suitably matched unrelated donor and this percentage 5 may be higher in certain non-Caucasian ethnic groups. Three large registry based studies have suggested that overall survival in adults receiving unrelated donor cord blood (CB) transplants for acute leukaemia is similar to that of patients receiving HLA-matched or mismatched URD bone marrow (BM) or peripheral blood progenitor cells (PBPC). [8] [9] [10] However, ALL in adults may have a different post-allografting natural history to acute myeloid leukemia making it necessary to do a focussed up-to-date study in this patient group.
CB cells result in a different profile of major transplant outcomes to adult URD stem cells. We wanted to examine if differences such as slower engraftment and potentially different rates of acute and chronic graft-versus-host disease (GVHD) might affect survival in adults being transplanted for ALL. In this study we compare outcomes after myeloablative transplant conditioning regimens for URD CB, BM and PBPC transplantations in adults with ALL in CR1 and CR2 and attempt to delineate prognostic factors associated with those outcomes.
METHODS

Eligibility criteria
Patients included were first allograft recipients, 16 years and older with ALL in CR1
or CR2 who had a single or double unit URD CB, BM or PBPC transplantation and received myeloablative conditioning. We excluded 20 patients older than 60 years of age because this cohort was insufficient for analysis and those with ALL -L3 (n = 3). Recipients of CB received units that were HLA-matched or mismatched at one or two HLA-loci. Donor-recipient matching 6 considered lower resolution HLA match (antigen-level) at HLA-A and -B and allele-level at HLA-DRB1. When two CB units were infused, the transplant was assigned the lowest unitrecipient HLA-match. Recipients of BM or PBPC received grafts matched at the allele-level at HLA-A, -B, -C, -DRB1 or mismatched at a single HLA-locus.
Endpoints
Neutrophil recovery was defined as achieving absolute neutrophil counts 0.5 x 10 9 /L for three consecutive measurements. Graft failure was defined as absence of neutrophil recovery or sustained loss after initial recovery. Incidences of grade 2-4 acute and chronic graft versus host disease (GVHD) were based on reports from each transplant center using standard criteria. 12, 13 Transplant-related mortality (TRM) was defined as death not related to disease recurrence and relapse, disease recurrence based on morphological evaluation.
Treatment failure was defined as death from any cause or relapse (inverse of leukemia-free survival -alive and in continuous clinical remission). Overall mortality was defined as death from any cause.
Statistical analysis
The probability of overall survival was calculated using the Kaplan-Meier estimator. 14 The probabilities of neutrophil and platelet recovery, acute and chronic GVHD, TRM and relapse were calculated using the cumulative incidence estimator to accommodate competing risks. 15 Cox proportional hazard regression models were constructed for acute and chronic GVHD, TRM, relapse, leukemia-free survival and overall mortality. 16 Results are expressed as hazard ratio (HR) with 95% confidence interval (CI were no first order interactions between the main effect term and other variables in the final models. All analyses were performed using SAS, version 9.3 (Cary, NC).
RESULTS
Patients: demographics, pre-transplant clinical, conditioning and graft characteristics
The characteristics of patients, their disease and transplantations are shown in Table 1 . /kg (sum of unit 1 and unit 2).
Transplantations using an adequately dosed single CB unit and infusion of two CB units were considered as a single group because an earlier report from our group did not show differences in transplant-outcomes. 17 Further, in the current analysis, the unadjusted 1-year overall survival after transplantation of one and two CB units was 54% and 51%, respectively 
Neutrophil and platelet recovery
As expected the median time to myeloid engraftment was longest in CB transplants (25 days), shortest in PBPC transplants (14 days) and 19 days in BM transplants (p<0.001).
At 28 days, the cumulative incidence of neutrophil recovery was significantly lower after CB 
Graft versus host disease
In multivariate analysis the risk of grade 2-4 acute GVHD was higher after 8/8 HLAmatched and 7/8 HLA-matched PBPC and BM transplants ( Chronic GVHD risks were not significantly different among the treatment groups ( 
Relapse
In multivariate analysis, after adjusting for disease status and duration of CR1, there were no significant differences in relapse risk between the treatment groups ( 
Transplant-related mortality
There were no significant differences in transplant-related mortality risks after CB transplants compared to the adult donor transplants ( Table 2 ). The 3-year cumulative incidence of transplant-related mortality after CB, 8/8 and 7/8 HLA-matched transplants were 42% (95% CI 33 -51), 31% (95% CI 27 -35) and 39% (95% CI 31 -47), respectively ( Figure 2 ). Age at transplantation and race were associated with transplant-related mortality.
Unsurprisingly there was a higher risk of transplant-related mortality in patients older than 35 
Overall and leukemia-free survival
Overall survival and leukemia-free survival were not significantly different between recipients of 8/8 or 7/8 adult donor grafts and CB ( 
DISCUSSION
In this retrospective comparative study of alternative donor sources using transplant registry data, survival did not differ significantly after CB and 7-8/8 BM or PBPC transplants for more than 800 adults with ALL in CR1 and CR2. This study differed from previous comparisons by only focussing on adult ALL. The groups differed in prognostic characteristics with CB transplant recipients being younger and having a better performance status and lower WBC but also being comprised of significantly more non-Caucasians and more patients in CR2. Nevertheless we performed a carefully controlled analysis adjusting for relevant clinical characteristics that allowed us to compare transplant-outcomes across the three treatment groups. Our findings extend and confirm reports from Japan. 19, 20 There are differences between that study and the current analysis. The current analysis includes adult donor transplantations matched at the allele-level at HLA-A, -B, -C and DRB1 or mismatched at a single HLA-locus, the current accepted standard for selecting unrelated adult donors. In contrast the Japanese group selected unrelated donors matched at HLA-A, -B and -C at lower resolution (antigen-level) and at the allele-level at -DRB1. Unlike the population in the United States with its greater genetic diversity transplantation using lower resolution HLA typing is better tolerated in the relatively homogenous Japanese island population.
Importantly, transplant-related mortality was high but similar in the three transplant groups (31-42% in absolute terms). As expected, CB patients were slower to achieve myeloid engraftment, there was twice the incidence of graft failure and platelet engraftment 13 was very slow and often incomplete. The less favourable hematopoietic recovery kinetics however, did not impact upon transplant-related mortality relative to adult donor transplants because adult donor transplant recipients were more likely to die from GVHD and/or infections. Nonetheless the finding of twice as much graft failure in the CB group is significant as nearly all patients with this complication died. Consistent with that reported by others, TRM was higher for non-Caucasians and independent of graft type. 21 A detailed exploration of the factors contributing to high TRM in non-Caucasians is beyond the scope of the current analyses. We hypothesize the higher TRM in non-Caucasians may be attributed multiple factors such as genetic polymorphism, unmeasured comorbidities, socio-economic status and health behaviours to mention a few.
Another significant finding was that relapse did not differ significantly between the three groups after adjusting for disease status and duration of CR1. The CB transplant group had more patients in CR2, more CR1 patients relapsed in the first 12 months and more received in vivo T cell depletion. This is an interesting comparison because CB was associated with less acute GVHD than PBPC grafts but similar amounts of chronic GVHD but less severe chronic GVHD. Although we know the incidence and severity of chronic GVHD in our patients groups we did not collect data on duration of treatment or their healthrelated quality of life. A large CIBMTR study 15 years ago reported a 40% reduction in relapse risks in ALL patients who got either acute and/or chronic GVHD. 22 In our study there was a suggestion that acute GVHD was associated with less relapse but there was no link with chronic GVHD. An important difference between the earlier report and the current analyses is sample size; it is plausible that with in a larger cohort the observed lower relapse risk associated with acute GVHD in the current may have been statistically significant.
Further, the earlier report 22 considered the combined effect of acute and chronic GVHD were as the current analyses explored for the effect separately for acute and chronic GVHD. In summary, centers performing myeloablative alternative donor transplants for adults with ALL in CR1 or CR2 should consider CB as a stem cell source from the outset because survival is broadly equivalent and transplant-related mortality and relapse are not increased.
Of course, haploidentical donor transplants, particularly with post-transplant cyclophosphamide, are a potential alternative stem cell source but larer studies with sufficient follow-up are required before they can be recommended. 27, 28 Finally it should be noted that the finding of the equivalence of the three graft sources only applies to myeloablative transplants. Reduced intensity conditioning 6,7 transplants will require a separate study when numbers are sufficient for analysis. 
Statistical analysis
Patient, disease and transplantation characteristics were compared using chisquare statistics for categorical variables ( Table 1 ). The probability of overall survival was calculated using the Kaplan-Meier estimator. 14 The probabilities of neutrophil and platelet recovery, acute and chronic GVHD, TRM and relapse were calculated using the cumulative incidence estimator to accommodate competing risks. 15 For TRM, relapse was the competing risk and for relapse, the competing risk was transplant-related mortality. For hematopoietic recovery, acute and chronic GVHD, death without the event was the competing risk. For analysis of overall survival, death from any cause was considered an event. For analysis of leukemia-free survival, relapse or death from any cause was considered an event. In all analyses, data on patients without an event were censored at last follow-up.
Cox proportional hazard regression models were constructed for acute and chronic GVHD, TRM, relapse, leukemia-free survival and overall mortality. 16 Results are expressed as hazard ratio (HR) with 95% confidence interval (CI). Multivariate models were built using stepwise selection procedure. Proportional-hazards assumption was tested for all variables considered in multivariate analysis and there were no violations. We first tested for differences in outcome between PBPC and BM by HLAmatch. Having established there were no significant differences between 8/8 PBPC vs. 
